IPK Superfamily
Inositiol Polyphosphate Kinase (IPK) Superfamily
Inositiol Polyphosphate Kinase (IPK) Superfamily is a family of enzymes that have a similar 3-dimensional structure. All members of the family catalyze the transfer of phosphate groups from ATP to various inositol phosphates. Members of the family include inositol-polyphosphate multikinases (IPMK), inositol-hexakisphosphate kinases, inositol-trisphosphate 3-kinases (PI3K) and inositol-pentakisphosphate 2-kinase (IP5P2K). Members of the IPK superfamily play important roles in various signaling pathways by altering the phosphorylation state of the second messenger inositol phosphates. Some members of the IPK superfamily are involved in regulating inositol phosphate metabolism related to vesicle transport, ensuring the accurate progress of intracellular substance transport. Abnormal functions of IPK superfamily members are closely related to the occurrence and development of various diseases, such as cancer, neurological diseases, and metabolic diseases[1][2][3].
References:
- [1]. Xiong T, et al. Origin, evolution, and diversification of inositol 1,4,5-trisphosphate 3-kinases in plants and animals. BMC Genomics. 2024 Apr 8;25(1):350.
- [2]. Malabanan MM, et al. Inositol polyphosphate multikinase (IPMK) in transcriptional regulation and nuclear inositide metabolism. Biochem Soc Trans. 2016 Feb;44(1):279-85. [Content Brief]
- [3]. Kim E, et al. IPMK: A versatile regulator of nuclear signaling events. Adv Biol Regul. 2016 May;61:25-32. [Content Brief]
All Product Categories
-
IPK Superfamily Related Products (13)
Related Products (13)
- 1
-
UNC7467
0 ImagesUNC7467 is a potent IP6K inhibitor with values of 4.9, 8.9 and 1320 nM for IP6K2, IP6K1 and IP6K6, respectively. UNC7467 reduces levels of inositol pyrophosphates. UNC7467 can be used for obesity research.
-
TNP
0 ImagesTNP is a competitive, reversible inhibitor of IP6K1 and IP3K, with IC50s of 0.55 μM and 10.2 μM for IP6K1 and IP3K, respectively. TNP competitively binds to the ATP binding site of IP6K, inhibits the generation of 5-IP7, and thus relieves the inhibition of 5-IP7 on the AKT signaling pathway. TNP can enhance insulin sensitivity and promote thermogenesis in adipose tissue. TNP cannot effectively pass through the blood-brain barrier and is mainly used in the study of obesity, type 2 diabetes, and metabolic syndrome. However, TNP also inhibits CYP3A4 and may need further optimization[1][2][3].
-
[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate
![[K15,R16,L27]VIP(1-7)/GRF(8-27) acetate](https://file.medchemexpress.com/product_pic/hy-p4195a.gif "Click to View [K15,R16,L27]VIP(1-7)/GRF(8-27) acetate Product Detail")
0 ImagesCat. No.: HY-P4195APurity: 99.50%[K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate) is the acetate of [K15,R16,L27]VIP(1-7)/GRF(8-27) (HY-P4195). [K15,R16,L27]VIP(1-7)/GRF(8-27) (acetate), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide
-
LI-2242
0 ImagesLI-2242 is an inositol hexakisphosphate kinase (IP6K) inhibitor. LI-2242 has inhibition effect for IP6K1, IP6K2, IP6K3 and IPMK with IC50 values of 31 nM, 42 nM, 8.7 nM and 1944 nM, respectively. LI-2242 can be used for thew research of type II diabetes, obesity, metabolic complications, venous thrombosis, and psychiatric disorders.
-
UNC7437
0 ImagesUNC7437 is a inositol phosphate multikinase (IPMK) inhibitor, with an IC50 value of 26.2 nM. UNC7437 exhibits anti-proliferative activity against glioblastoma cells. UNC7437 decreases the accumulation of InsP4, InsP5, and InsP6 in cells. UNC7437 can be used for the study of TEN-negative glioblastoma models.
-
IP6K-IN-2
0 ImagesCat. No.: HY-185141CAS No.: 3024590-83-5IP6K-IN-2 is an inositol hexakisphosphate kinase (IP6K1) inhibitor that inhibits IP6K1 enzyme activity with an IC50 value of 110 nM. IP6K-IN-2 can be used for the research of neurological disease and CNS disorders.
-
IP6K2-IN-1
0 ImagesIP6K2-IN-1 is a selective flavonoid-based IP6K2 inhibitor with an IC50 value of 0.55 μM. IP6K2-IN-1 shows higher inhibitory potency against IP6K2 than IP6K1 and IP6K3. IP6K2-IN-1 can be utilised as a hit compound for further structural modifications of IP6K2 inhibitors.
-
SC-919
0 ImagesSynonyms: LI-2124SC-919 is an orally active IP6K inhibitor, with an IC50 of < 5.2 nM against IP6K1, < 3.8 nM against IP6K2, and 0.65 nM against IP6K3. By inhibiting the activity of IP6K, SC-919 reduces intracellular IP7 levels, thereby suppressing XPR1-mediated cellular phosphate efflux. SC-919 increases intracellular phosphate and ATP levels while reducing phosphate entry into the bloodstream, thus decreasing plasma phosphate levels. SC-919 can be used in research related to chronic kidney disease and hyperphosphatemia.
-
IP6K-IN-1
0 ImagesIP6K-IN-1 (compound 24) is a potent and selective inhibitor of IP6K with an IC50 of 0.896 μM. IP6K-IN-1 can used in study metabolic disease.
-
IP6K2-IN-2
0 ImagesIP6K2-IN-2 (Compound 6) is an IP6K2 inhibitor, with IC50 values of 0.58 μM (IP6K2), 0.86 μM (IP6K1) and 3.08 μM (IP6K3). IP6K2-IN-2 can be used in research of obesity.
-
[K15,R16,L27]VIP(1-7)/GRF(8-27)
![[K15,R16,L27]VIP(1-7)/GRF(8-27)](https://file.medchemexpress.com/product_pic/hy-p4195.gif "Click to View [K15,R16,L27]VIP(1-7)/GRF(8-27) Product Detail")
0 ImagesCat. No.: HY-P4195CAS No.: 201995-58-6[K15,R16,L27]VIP(1-7)/GRF(8-27), a VIP1 selective agonist, exhibits IC50 values of binding of 2 nM, 1 nM, 30,000 nM for the human VIP1, rat VIP1, rat VIP2 receptors, respectively. VIP: VASOACTIVE Intestinal Polypeptide
-
LI-3948
0 ImagesCat. No.: HY-162821CAS No.: 3024591-38-3IP6K-IN-2 (compound 29c) is an orally bioavailable and blood-brain barrier permeable IP6K inhibitor (IC50: 15.8 nM) that can be used in the study of central nervous system diseases.
-
UNC9750
0 ImagesCat. No.: HY-175477CAS No.: 2967648-29-7UNC9750 is an inositol phosphate multikinase (IPMK) inhibitor with IC50 values of 31.6 and 374 nM for IPMK and IP6K2, respectively.. UNC9750 inhibits cellular accumulation of InsP5, the direct product of IPMK kinase activity, while having no effect on either InsP6 or InsP7 levels. UNC9750 has ≥ 75% inhibition of four kinases (DAPK1, DYRK1B, PDGFR, and KDR). UNC9750 can be used for the study of glioblastoma.
- 1
